A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF TWO DOSES OF FAVIPIRAVIR IN ADULT PATIENTS WITH UNCOMPLICATED INFLUENZA

Toyama Chemical Co., Ltd.,0 个研究点目标入组 5 人开始时间: 2010年7月15日最近更新: 2023年9月4日

试验速览

暂无简介。

•1.Patients who test positive for influenza A or B by a commercially available Rapid
•Antigen Test (RAT) of the nasopharynx. A patient with a negative RAT result may still
•enroll if the sponsor and investigator agree that there is a known influenza outbreak
•circulating in the community.
•2.Patients = 20 but < 65 years of age with a temperature (oral) of 100.4°F (38.0°C) or
•more; patients = 65 years of age with a temperature (oral) of 100.0°F (37.8°C) or
•more at the first visit, or in the 6 hours prior if antipyretics were taken.
•3. Patients with 2 or more of the following symptoms (moderate to severe in intensity)
•at the time of enrollment:
•- Sore throat
•- Headache
•- Nasal congestion
•- Feeling feverish
•- Body aches and pains
•- Fatigue (tiredness)

•1. Patients who have had influenza symptoms or fever (i.e., one of the symptoms listed
•under the inclusion criteria) for 36 hours or more prior to study screening.
•2.Patients who have underlying chronic respiratory disease (e.g., chronic obstructive
•pulmonary disease [COPD], chronic bronchitis, diffuse panbronchiolitis,
•bronchiectasis, pulmonary emphysema, pulmonary fibrosis, bronchial asthma, or old
•tuberculosis)
•3. Patients who at the beginning of the study are suspected of having bacterial
•respiratory infection (i.e., expectoration of purulent or mucopurulent sputum and/or
•infiltrate in lung in a chest x-ray, etc.).
•4. Patients who have serious chronic diseases. For example, patients with HIV, cancer
•(i.e., requiring chemotherapy within the preceding 6 months), cirrhosis (end-stage),
•and/or unstable renal, cardiac, pulmonary, neurologic, vascular, or endocrinologic
•disease states requiring medication dose adjustments within the last 30 days.

发起方